Menu Search
Equities

Wellnex Life Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
22W0:FRA

Wellnex Life Ltd

Actions
  • Price (EUR)0.0555
  • Today's Change-0.005 / -8.26%
  • Shares traded20.00k
  • 1 Year change-85.16%
  • Beta1.6983
Data delayed at least 15 minutes, as of Feb 16 2026 07:12 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Wellnex Life Limited is an Australia-based health and wellness company, which is engaged in the consumer healthcare business. The Company is developing, licensing, and marketing registered products and brands to customers in the healthcare market segment. Its brands include Wakey Wakey, Nighty Night, Pharmacy Own, Mr Bright and Pain Away. The Company has intellectual property (IP)-licensing agreements with Haleon and Arrotex. The Company, through a joint venture with OneLife Botanical and Chemist Warehouse for SAS-B medicinal cannabis under the Wellness Life brand. It has launched a Therapeutic Goods Administration (TGA)-approved soft gel liquid paracetamol product in a jointly owned brand with retailer Chemist Warehouse under the Wagner Liquigesic brand. Mr Bright is a natural tooth whitening brand, which is being sold in the United Kingdom through Boots and TJ Maxx retail stores and is available online domestically.

  • Revenue in AUD (TTM)23.63m
  • Net income in AUD-15.60m
  • Incorporated2011
  • Employees--
  • Location
    Wellnex Life Ltd17 / 71 Victoria Crescent, AbbotsfordMELBOURNE 3207AustraliaAUS
  • Phone+61 38399-9419
  • Websitehttps://wellnexlife.com.au/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.